Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

Bellmunt, 2012, Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987, J Clin Oncol, 30, 1107, 10.1200/JCO.2011.38.6979 Von der Maase, 2000, Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study, J Clin Oncol, 18, 3068, 10.1200/JCO.2000.18.17.3068 Sonpavde, 2014, Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer, Clin Genitourin Cancer, 12, 71, 10.1016/j.clgc.2013.11.016 Galsky, 2011, Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy, J Clin Oncol, 29, 2432, 10.1200/JCO.2011.34.8433 Ortmann, 2013, Second-line systemic therapy for metastatic urothelial carcinoma of the bladder, Future Oncol, 9, 1637, 10.2217/fon.13.139 Raggi, 2016, Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis, Ann Oncol, 27, 49, 10.1093/annonc/mdv509 Boorjian, 2008, T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival, Clin Cancer Res, 14, 4800, 10.1158/1078-0432.CCR-08-0731 Faraj, 2015, Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma, Urology, 85, 703, 10.1016/j.urology.2014.10.020 Inman, 2007, PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression, Cancer, 109, 1499, 10.1002/cncr.22588 Rosenberg, 2016, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, Lancet, 387, 1909, 10.1016/S0140-6736(16)00561-4 Ansell, 2015, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N Engl J Med, 372, 311, 10.1056/NEJMoa1411087 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643 Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, 373, 123, 10.1056/NEJMoa1504627 Motzer, 2015, Nivolumab versus everolimus in advanced renal-cell carcinoma, N Engl J Med, 373, 1803, 10.1056/NEJMoa1510665 Robert, 2015, Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med, 372, 320, 10.1056/NEJMoa1412082 Sharma, 2016, Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm phase 1/2 trial, Lancet Oncol, 17, 1590, 10.1016/S1470-2045(16)30496-X Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Aaronson, 1993, The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J Natl Cancer Inst, 85, 365, 10.1093/jnci/85.5.365 Osoba, 1998, Interpreting the significance of changes in health-related quality-of-life scores, J Clin Oncol, 16, 139, 10.1200/JCO.1998.16.1.139 1990, EuroQol—a new facility for the measurement of health-related quality of life, Health Policy, 16, 199, 10.1016/0168-8510(90)90421-9 Pickard, 2007, Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer, Health Qual Life Outcomes, 5, 70, 10.1186/1477-7525-5-70 Choi, 2014, Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer, Nat Rev Urol, 11, 400, 10.1038/nrurol.2014.129 Bellmunt, 2010, Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens, J Clin Oncol, 28, 1850, 10.1200/JCO.2009.25.4599 Massard, 2016, Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer, J Clin Oncol, 34, 3119, 10.1200/JCO.2016.67.9761 Plimack, 2017, Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study, Lancet Oncol, 10.1016/S1470-2045(17)30007-4 Choueiri, 2012, Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer, J Clin Oncol, 30, 507, 10.1200/JCO.2011.37.7002 Hainsworth, 2005, Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium, Cancer, 103, 2298, 10.1002/cncr.21078 Zaretsky, 2016, Mutations associated with acquired resistance to PD-1 blockade in melanoma, N Engl J Med, 375, 819, 10.1056/NEJMoa1604958 Gao, 2016, Loss of IFN-γ signaling in tumor cells as a mechanism of primary resistance to anti-CTLA-4 therapy, Cell, 167, 397, 10.1016/j.cell.2016.08.069